Lymphoma
If it’s your first time on this website, please read the disclaimer section.
May 25 – Jun 01, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3, randomised, double-blind, placebo-controlled multicentre clinical trial evaluated tafasitamab plus lenalidomide added to standard R-CHOP versus R-CHOP alone as first-line treatment for untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in 899 adult patients. Patients received six 21-day cycles with stratified random assignment; progression-free survival was the primary endpoint. At median follow-up of 35.2 months, the tafasitamab-lenalidomide-R-CHOP group had a hazard ratio for progression-free survival of 0.75 (95% CI 0.59-0.96, p=0.0194) and a 2-year progression-free survival rate of 71.1% versus 62.9% for R-CHOP alone; grade 3 or higher adverse events were more frequent with tafasitamab-lenalidomide-R-CHOP (87% vs 76%). The trial concluded tafasitamab-lenalidomide-R-CHOP may offer a new first-line option, but with increased adverse event rates.
10.1016/S0140-6736(26)00866-4
May 18 – May 25, 2026
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This double-blind, placebo-controlled phase 3 randomized clinical trial evaluated the efficacy and safety of tucidinostat plus R-CHOP versus R-CHOP alone as a first-line treatment for patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). A total of 423 patients participated, with a median follow-up of 41.3 months. Tucidinostat reduced the risk of disease progression, relapse, death, or need for new therapy by 28% (HR, 0.72 [95% CI, 0.54-0.96]; P = .02) and improved the 2-year event-free survival rate (60.3% vs. 50.5%) and complete response rate (73.0% vs. 61.8%; difference 11.1% [95% CI, 2.3%-20.0%]). The trial demonstrated that tucidinostat plus R-CHOP significantly improves survival outcomes with manageable toxicity, representing a novel first-line treatment for this high-risk patient population.
10.1001/jama.2026.4199
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This expanded phase I/II prospective clinical trial evaluated the efficacy and safety of bispecific CD19/20 CAR-T cell therapy in 32 patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL), following lymphodepletion. Efficacy endpoints included an overall response rate of 74% (58% complete remission among 31 evaluable patients), with median progression-free and overall survival of 6.8 and 22.1 months, respectively. Adverse events were manageable, with cytokine release syndrome in 53% (12% grade ≥3) and neurotoxicity in 9% (all grade 3, no sequelae). Spatial single-cell transcriptomics of tumor biopsies identified distinct microenvironmental phenotypes correlating with responsiveness, informing mechanisms underlying differential outcomes.
10.1136/jitc-2026-015114
May 11 – May 18, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This European, three-arm, randomised, open-label phase 3 TRIANGLE trial enrolled 870 previously untreated mantle cell lymphoma patients aged 18-65 years and allocated them to standard R-CHOP/R-DH(A)P followed by autologous stem-cell transplantation (ASCT) (A), the same regimen plus ibrutinib with post-ASCT ibrutinib maintenance (A+I), or the ibrutinib-containing regimen without ASCT but with 2-year ibrutinib maintenance (I). After a median 54.9-month follow-up, 4-year failure-free survival was 70 % for A, 82 % for A+I (HR 0.63, one-sided p = 0.0026), and 81 % for I; A+I was not superior to I (HR 0.86, p = 0.21). Four-year overall survival reached 88 % in A+I and 90 % in I versus 81 % in A, while grade 3-5 hematologic events were more common with ASCT plus ibrutinib (54 %) than with I (28 %) or A (23 %). The investigators conclude that ibrutinib-based induction and maintenance yields survival benefits and that adding ASCT adds toxicity without benefit, suggesting a new standard of care omitting upfront ASCT.
10.1016/S0140-6736(26)00362-4
RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.
AM J HEMATOL · Q1 JOURNAL - RANK #10/98
This prospective, single-arm, multicenter Phase II trial (RCLARITY) evaluated rituximab, lenalidomide, and chidamide (RLC) in 28 adult patients with relapsed/refractory angioimmunoblastic T-cell lymphoma. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall response rate (ORR), overall survival (OS), and safety. Key results showed an ORR of 71.4% (complete remission 32.1%), median PFS of 5.5 months (95% CI 3.5-7.6), and median OS of 17.6 months (95% CI 10.3-24.8). The regimen demonstrated manageable toxicity with no grade 5 adverse events, supporting its anti-tumor activity in this poor-prognosis population.
10.1002/ajh.70366
May 04 – May 11, 2026
Building on CD19 based therapy for relapse or refractory follicular lymphoma.
MED-CAMBRIDGE · Q1 JOURNAL - RANK #11/195TOP-TIER
This phase III inMIND trial evaluated whether tafasitamab plus lenalidomide and rituximab (R) improved outcomes in relapsed/refractory follicular lymphoma. This randomized study compared tafasitamab plus lenalidomide and R versus lenalidomide and R alone. The combination reduced the risk of progression or death by 57%, prolonging median PFS from 13.9 to 22.4 months (HR 0.43; p<0.0001) with slightly increased infections. These findings confirm a safe and effective regimen for patients ineligible for T-cell-engaging therapies.
10.1016/j.medj.2026.101101
Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results.
J CLIN MED · Q1 JOURNAL - RANK #65/332
This prospective, non-randomized clinical trial evaluated the feasibility, efficacy, and safety of a genotype-directed R-CHOP-X therapy in 43 adults with newly diagnosed DLBCL, using molecular profiling to tailor additional agents (vorinostat, acalabrutinib, decitabine, or lenalidomide). The study reported a 100% overall response rate, 100% complete response in therapy completers, and two-year overall and progression-free survival rates of 92% and 94%, respectively, with manageable toxicity (grade 3-4 neutropenia in 26%). The findings suggest molecularly adapted R-CHOP-X is feasible and effective, warranting further validation in randomized trials.
10.3390/jcm15082983
Apr 27 – May 04, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
LANCET HAEMATOL · Q1 JOURNAL - RANK #3/98TOP-TIER
This open-label, multicentre, phase 1/2 BRUIN trial prospectively evaluated pirtobrutinib in 80 patients with relapsed or refractory Waldenström macroglobulinaemia. Patients received 100-300 mg oral pirtobrutinib daily, with a recommended phase 2 dose of 200 mg; the primary endpoint was objective response rate per IWWM-6 criteria. With a median 35.0-month follow-up, the objective response rate was 82.5% (95% CI 72.4-90.1), including 81.0% in patients previously treated with covalent BTK inhibitors and 88.2% in BTK inhibitor-naive patients; grade ≥3 adverse events occurred in 71% of patients. The authors conclude pirtobrutinib is highly active and well tolerated, offering a promising option for relapsed or refractory Waldenström macroglobulinaemia, particularly after prior covalent BTK inhibitor exposure.
10.1016/S2352-3026(26)00037-2
Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.
CELL · Q1 JOURNAL - RANK #3/319TOP-TIER
This first-in-human study (NCT01087294) investigates the dynamics, efficacy, and safety profile of donor-derived CAR-modified stem-cell memory T (TSCM) cells for B cell malignancies relapsing after allogeneic hematopoietic stem cell transplantation. Through a comparative assessment, TSCM cells demonstrated superior expansion, persistence, and reconstitution of the stem-like compartment over time compared to standard CAR T cells, achieving complete responses at lower doses without lymphodepletion. Mild cytokine-release syndrome was observed, dominated by IFN-γ, with tumor- and host-related factors contributing to resistance against TSCM cells. The study concludes that CAR TSCM cells are a promising platform for the development of next-generation CAR T cell therapies targeting relapsed B cell malignancies.
10.1016/j.cell.2026.03.047
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.
HEMATOL ONCOL · Q1 JOURNAL - RANK #23/98
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated CNS prophylaxis using intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in 100 patients with diffuse large B-cell lymphoma (DLBCL), stratified by CNS-IPI risk. Primary outcomes included CNS relapse incidence (0% in arm A vs. 8.7% in arm B, p=0.72), with no significant difference in ORR (p=0.20) or PFS (HR 0.66, p=0.20), but i.v. MTX showed higher grade ≥3 neutropenia (p=0.0003) and infection rates (p=0.0063), leading to worse 5-year OS (47.2% vs. 72.4%, HR 0.46, p=0.04). The study concluded that the small sample size limited interpretability, necessitating larger trials to assess CNS prophylaxis efficacy. The trial design and reporting of active cancer treatment outcomes align with inclusion criteria, while excluding non-interventional or non-cancer-related interventions.
10.1002/hon.70193
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The study evaluated circulating tumor DNA (ctDNA) as a biomarker for disease response in a prospective clinical trial comparing lisocabtagene maraleucel (liso-cel) versus standard therapy (autologous stem cell transplantation [ASCT]) in 136 patients with second-line large B-cell lymphoma (LBCL). Using ultrasensitive PhasED-Seq, ctDNA clearance (measurable residual disease [MRD]) was assessed at predefined time points, showing liso-cel-treated patients achieved MRD more frequently and had superior outcomes, including longer event-free survival (EFS) and progression-free survival (PFS). ctDNA re-emergence predicted relapse, and MRD remained significantly associated with EFS after adjusting for PET response, demonstrating its prognostic value beyond imaging. The study concludes that ctDNA-MRD is a complementary biomarker for treatment response and relapse prediction in LBCL.
10.1200/JCO-25-03051
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
This single-arm, multi-center phase 2 trial examined the efficacy and safety of abexinostat, a histone deacetylase inhibitor, in relapsed or refractory follicular lymphoma. Ninety patients who had received at least two prior systemic treatments were given abexinostat 80 mg twice daily on a 7-on/7-off schedule in 28-day cycles. The objective response rate was 69.5% (57/82), median progression-free survival was 13.80 months, and median overall survival was 47.18 months. Abexinostat exhibited promising efficacy with a manageable safety profile, supporting its application as a potential third-line or later treatment option for r/r FL.
10.1038/s41392-026-02646-z
Apr 20 – Apr 27, 2026
Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.
HAEMATOLOGICA · Q1 JOURNAL - RANK #11/98
This study analyzed baseline circulating tumor DNA (ctDNA) from the Phase 3 GALLIUM trial, a prospective clinical trial comparing obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in untreated follicular lymphoma. ctDNA levels, measured as mutant molecules per milliliter, predicted progression within 24 months with an AUROC of 0.69, outperforming FLIPI (0.57), FLIPI-2 (0.59), and SPD (0.58). High baseline ctDNA (>168.57 MMPM) was significantly associated with shorter progression-free survival (HR=2.2, 95% CI 1.8-2.6), and this prognostic value was maintained across different chemotherapy regimens. The authors conclude that baseline ctDNA is a robust prognostic biomarker for untreated follicular lymphoma patients receiving standard chemoimmunotherapy.
10.3324/haematol.2025.289111
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.
ESMO OPEN · Q1 JOURNAL - RANK #36/326
This post hoc analysis of the phase II ROSEWOOD trial evaluated the comparative efficacy of zanubrutinib plus obinutuzumab (ZO) versus patients’ last prior treatment for relapsed/refractory follicular lymphoma using the growth modulation index (GMI). The prospective, interventional trial randomized patients to receive ZO or obinutuzumab monotherapy (O) after two or more prior lines of systemic therapy. Median progression-free survival was 28.0 months with ZO versus 10.4 months with O (HR 0.50, 95% CI 0.33-0.75), and median GMI was 2.7 (95% CI 1.6-4.9) for ZO versus 0.9 (95% CI 0.5-1.7) for O, with >60% of ZO patients achieving GMI ≥1.33. The analysis supports ZO as a novel therapeutic option, demonstrating improved efficacy compared to both the control arm and patients’ prior treatments.
10.1016/j.esmoop.2026.106942
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.
HEMASPHERE · Q1 JOURNAL - RANK #5/98TOP-TIER
This prospective phase 2 clinical trial (ELM-2, NCT03888105) evaluated the dynamics of complete responses in patients with relapsed/refractory follicular lymphoma treated with odronextamab, a CD20×CD3 bispecific antibody. Patients received intravenous odronextamab with step-up dosing followed by weekly and then bi-weekly maintenance dosing, with a subset switching to every-4-week dosing after sustained response. The study achieved a 73.4% (94/128) complete response rate with median duration of 25.1 months, and 79.5% (35/44) of patients who switched to extended dosing maintained CR at last assessment. The authors concluded that odronextamab demonstrates deep, durable responses with manageable safety, supporting its potential as long-term treatment for heavily pretreated patients.
10.1002/hem3.70300
Apr 13 – Apr 20, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
The study is a phase I/II trial evaluating the safety and efficacy of demethylation-primed CD19/CD20 dual-targeted CAR T cells (dCAR T) in 23 patients with relapsed or refractory non-Hodgkin lymphoma (NHL). The open-label, non-randomized trial (NCT04697940) assessed primary endpoints (safety, dose-toxicity, overall response rate, and complete response rate) and secondary endpoints (progression-free survival, overall survival, and duration of response). Key findings include an 87% complete response rate (CRR) and a 2-year progression-free survival (PFS) of 77% (median follow-up, 24.3 months), with dCAR T cells showing robust in vivo expansion and sustained persistence. The study concludes that DAC-priming enhances CAR T durability and efficacy, offering a clinically feasible epigenetic reprogramming strategy for engineered cell therapies in malignant tumors.
10.1038/s41467-026-72040-4
Apr 06 – Apr 13, 2026
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This multicenter, open-label, single-arm phase Ib trial evaluated the anti-TIM-3 antibody TQB2618 combined with the anti-PD-1 antibody penpulimab in relapsed or refractory classical Hodgkin lymphoma (cHL) that had progressed after prior PD-1/PD-L1 therapy. In a dose-escalation cohort (600 or 1200 mg TQB2618 plus penpulimab 200 mg every 3 weeks) followed by a dose-expansion cohort at the recommended phase II dose (600 mg), 21 patients with r/r cHL were treated. At a median follow-up of 14.1 months, the objective response rate was 52 % (1 complete and 10 partial responses), while treatment-related adverse events occurred in 86 % of patients, with grade ≥3 events in 24 %; the most common TRAEs (≥20 %) were thrombocytopenia, anemia, and elevated AST. The authors conclude that TQB2618 plus penpulimab is tolerable and shows promising activity in this heavily pretreated cHL population, warranting further study.
10.1136/jitc-2026-014968
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
AM J HEMATOL · Q1 JOURNAL - RANK #10/98
The primary objective of this pivotal phase 2 study was to evaluate pharmacokinetics, efficacy, and safety of fixed-duration subcutaneous mosunetuzumab in patients with relapsed/refractory follicular lymphoma after at least two prior therapies, compared to an intravenous formulation. Ninety-four patients received subcutaneous mosunetuzumab, with a median follow-up of 26.1 months, while a within-study comparator arm included 90 patients treated intravenously. Key findings include non-inferior pharmacokinetic exposure (e.g., GMR for Cmax 1.39, AUC 1.06), an overall response rate of 76.6%, complete response rate of 61.7%, median duration of complete response 34.6 months, and median progression-free survival of 23.7 months; the subcutaneous arm also showed lower rates and severity of cytokine release syndrome. The study concluded that subcutaneous mosunetuzumab offers comparable efficacy, improved safety, and greater patient convenience versus intravenous administration.
10.1002/ajh.70225